# Jean-Francois Formela

> Jean-Francois Formela is a Series A investor at Atlas Venture backing Biotechnology. See 21 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Atlas Venture](https://shizune.co/investors/profile/atlas-venture)
- Location: Cambridge, United States
- Total investments: 21
- Last investment: May 2025
- Lead investor: 38%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/jean-francois-formela-14b1817

Jean-Francois Formela is a Series A investor at Atlas Venture in Cambridge focused on Biotechnology and Health Care. Jean-François Formela is a partner and focuses on new advances in biology and drug discovery technologies as well as novel therapeutics.He serves on the boards of Ataxion, Egalet (NASDAQ: EGLT), F-star, Intellia Therapeutics, Navitor, RaNA Therapeutics which he co-founded, Spero Therapeutics and ZappRx. Jean-François has been involved inthe formation of companies such as Adnexus (acquired by BMS), ArQule (NASDAQ: ARQL), Annovation Biopharma (acquired by The Medicines Company), Arteaus Therapeutics (acquired by Lilly), Cellzome (acquired by GSK), deCODE (NASDAQ: DCGN, acquired by Amgen), Exelixis (NASDAQ: EXEL), MorphoSys (Xetra: MOR.DE), NxStage (NASDAQ: NXTM) and SGX Pharmaceuticals (NASDAQ: SGXP, acquired by Lilly). He was also an investor in Achillion (NASDAQ: ACHN), CoStim Pharmaceuticals (acquired by Novartis) and Horizon Pharma (NASDAQ: HZNP) as well as a board member of Biochem Pharma (NASDAQ: BCHE, acquired by Shire) and Novexel (acquired by AstraZeneca).Jean-François joined Atlas Venture in 1993 to build the U.S. life sciences franchise. Prior to joining Atlas, Jean-François worked at Schering-Plough, where he directed U.S. Phase IV studies in all therapeutic areas. Before that, he was responsible for the marketing of Intron A, Schering-Plough’s alpha-interferon. Jean-François began his career as a medical doctor and practiced emergency medicine at Necker University Hospital in Paris.Jean-François is a member of the Massachusetts General Hospital Research Advisory Council and a former trustee of the Boston Institute of Contemporary Art.He received his MD from Paris University School of Medicine, and his MBA from Columbia University.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 12 | 57% |
| Health Care | 8 | 38% |
| Therapeutics | 7 | 33% |
| Medical | 4 | 19% |
| Biopharma | 4 | 19% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 10 | 48% |
| Series B | 5 | 24% |
| Series C | 3 | 14% |
| Seed | 1 | 5% |
| Funding Round | 1 | 5% |

6 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Antares Therapeutics | Antares Therapeutics is a biotechnology company focused on developing transformational precision medicines targeting validated but previously undruggable targets in cancer and other serious diseases with significant unmet medical needs. Founded as a spin-out from Scorpion Therapeutics, it leverages proprietary drug discovery capabilities and arobust preclinical pipeline to advance multiple programs, primarily in precision oncology. | $177M | Series A | May 15, 2025 |  |
| Triveni Bio | Triveni Bio is at the forefront of human genetics, cutting-edge antibody design, and precision medicine, pioneering the identification of new disease targets. | $115M | Series B | Oct 02, 2024 |  |
| Scorpion Therapeutics | Scorpion Therapeutics was founded to broaden the reach and impact of precision medicine to more people with cancer. The company is integrating cutting-edge technologies across target discovery, medicinal chemistry, and translational medicine to deliver Precision Oncology 2.0. Scorpion’s experienced leadership team is executing a fit-to-purposemodel to efficiently unlock the next generation of precision oncology. | $150M | Series C | Jul 16, 2024 |  |
| Triveni Bio | Triveni Bio is at the forefront of human genetics, cutting-edge antibody design, and precision medicine, pioneering the identification of new disease targets. | $92M | Series A | Oct 26, 2023 |  |
| Korro Bio | Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms.Korro Bio was created to lead the field of RNA editing. The company is advancing a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in proteinstructure and function across multiple tissues.In 2018, | $116M | Series B | Jan 05, 2022 |  |
| Scorpion Therapeutics | Scorpion Therapeutics was founded to broaden the reach and impact of precision medicine to more people with cancer. The company is integrating cutting-edge technologies across target discovery, medicinal chemistry, and translational medicine to deliver Precision Oncology 2.0. Scorpion’s experienced leadership team is executing a fit-to-purposemodel to efficiently unlock the next generation of precision oncology. | $162M | Series B | Jan 07, 2021 |  |
| Scorpion Therapeutics | Scorpion Therapeutics was founded to broaden the reach and impact of precision medicine to more people with cancer. The company is integrating cutting-edge technologies across target discovery, medicinal chemistry, and translational medicine to deliver Precision Oncology 2.0. Scorpion’s experienced leadership team is executing a fit-to-purposemodel to efficiently unlock the next generation of precision oncology. | $108M | Series A | Oct 26, 2020 |  |
| Korro Bio | Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms.Korro Bio was created to lead the field of RNA editing. The company is advancing a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in proteinstructure and function across multiple tissues.In 2018, | $91.5M | Series A | Sep 10, 2020 |  |
| Triplet Therapeutics | Triplet is developing transformative therapies that treat repeat expansion disorders at their source. | $49M | Series A | Dec 17, 2019 |  |
| IFM Therapeutics | IFM Therapeutics is a provider of small molecule that module novel targets in the innate immune system. The company and its academic collaborators combine unparalleled expertise in innate immunity with seasoned drug discovery and development professionals. Its subsidiary IFM Due is focused on the discovery and developing antagonists of thecGAS/STING pathway for the treatment of inflammation, neuroinflammation, autoimmunity and cancer. IFM Discovery, a newly financed incubator entity within the IFM enterprise, is prosecuting a basket of genetically-validated targets as next-generation therapies for inflammation, neuroinflammation, autoimmunity and fibrosis | $55.5M |  | Dec 02, 2019 |  |

10 of 21 investments shown.

## Co-investors
- [Omega Funds](https://shizune.co/investors/profile/omega-funds) — VC Fund, 10 deals together
- [Invus](https://shizune.co/investors/profile/invus) — VC Fund, 6 deals together
- [Cormorant Asset Management](https://shizune.co/investors/profile/cormorant-asset-management) — VC Fund, 5 deals together
- [Lightspeed Venture Partners](https://shizune.co/investors/profile/lightspeed-venture-partners) — VC Fund, 5 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 5 deals together
- [Abingworth](https://shizune.co/investors/profile/abingworth-management) — VC Fund, 4 deals together

## About Atlas Venture

VC Fund · Cambridge, United States

Atlas Venture is an early-stage venture capital firm that creates and invests in biotech startup companies led by promising entrepreneurs focusing on life sciences innovation. Its seed-led venture creation strategy rigorously selects and focuses investment on compelling opportunities to build scalable businesses and realize value.

5 contacts available at Atlas Venture.

| Name | Title | Profile |
| --- | --- | --- |
| Chelsea Place Johnson | Principal | https://shizune.co/investors/profile/chelsea-place-johnson |
| Ed Holson | Entrepreneur-in-Residence | https://shizune.co/investors/profile/ed-holson |
| Jean-Francois Formela | Partner | https://shizune.co/investors/profile/jean-francois-formela |
| Kevin Bitterman | Partner | https://shizune.co/investors/profile/kevin-bitterman |
| Michael Gladstone | Principal | https://shizune.co/investors/profile/michael-gladstone |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Jean-Francois Formela invest in?

Jean-Francois Formela invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 21 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Jean-Francois Formela last invest?

The most recent investment recorded for Jean-Francois Formela closed in May 2025. Shizune tracks 21 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co